AUAUniversity

Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation and innovation. Patient communication, including goal setting with respect to realistic expectations of therapy, and therapeutic algorithms are important factors in improving patient outcomes. The publication of the recently updated AUA/SUFU Guideline entitled "Diagnosis and Treatment of Overactive Bladder (Non-neurogenic) in Adults, the proceedings of the 5th International Consultation on Incontinence," as well as European Association of Urology (EAU) Guidelines, has rekindled interest in this area. This course will describe the physiological and pharmacological underpinnings of modern drug treatment of overactive bladder including combination therapy. Currently available agents as well as drugs in development will be discussed.

CME Available: https://auau.auanet.org/content/contemporary-pharmacotherapy-oab-webcast-031ic-2018

Dr. Nitti and Dr. Davis discus the use of focal therapy in the treatment of prostate cancer. @jdhdavis - This file has been updated

The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on:

Discussing the evolving landscape of adjuvant therapy for the treatment of kidney cancer and debating the elements of disagreement in this area.

Differentiating the roles of urologist and medical oncologist in the care of patients with kidney cancer.

Appreciating the patient’s journey through RCC and identifying their needs as it relates to the coordination of care between the urologists and medical oncologists.

CME: https://auau.auanet.org/content/highlights-renal-cell-carcinoma-evolving-landscape-adjuvant-therapy-2018

The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on:

Discussing the evolving landscape of adjuvant therapy for the treatment of kidney cancer and debating the elements of disagreement in this area.

Differentiating the roles of urologist and medical oncologist in the care of patients with kidney cancer.

Appreciating the patient’s journey through RCC and identifying their needs as it relates to the coordination of care between the urologists and medical oncologist.

CME Available: https://auau.auanet.org/content/highlights-renal-cell-carcinoma-roles-urologist-and-medical-oncologist-2018

This course will review the 2015 update to the 2013 AUA guidelines on castration-resistant prostate cancer. Faculty will explore the rigorous process used in the development of these evidence-based guidelines, as well as discuss new developments and future research needs for this topic. The course will showcase clinical scenarios in urological practice and the correct application of the new AUA guidelines in those instances. This course will be a benefit to practicing urologists, non-physician providers, residents preparing for their certification exam and physicians preparing for their re-certification exam.

CME Available: https://auau.auanet.org/content/aua-castration-resistant-prostate-cancer-crpc-guidelines-webcast-074ic-2018

The American Urological Association (AUA) recognizes the critical role of the primary care provider in treating patients with urologic conditions. The AUA is pleased to offer this Podcast on one of the urologic topics most relevant to front-line patient care—Overactive Bladder (OAB). This OAB Podcast, recorded live at the 2018 AUA Annual Meeting, was recorded specifically for primary care providers and explores the following topics: the physiological and pharmacological underpinnings of modern drug treatment of overactive bladder including combination therapy; currently available agents as well as drugs in development; patient communication, including goal setting with respect to realistic expectations of therapy, and therapeutic algorithms; and more. Get the latest updates on this topic from the experts!

You can also earn free CME for this Podcast! You can easily create an AUA account and earn free CME for this Podcast.

Access at https://auau.auanet.org/AUA2018/contemporary-pharmacotherapy-oab-broadcast.

Steven A Kaplan, MD joins Dr. Nitti to discuss Minimally Invasive Treatment Of BPH. Dr. Kaplan is Professor of Urology at the Icahn School of Medicine at Mount Sinai and Director of Benign Urologic Diseases and The Men’s Health Program of the Mount Sinai Health System.

Dr Nitti and Dr. Daneshmand discuss the AUA Update Series Article titled "Update on Medical and Surgical Management of Advanced Testis Cancer"

This episode will describe and explain the current recommendations for imaging; indications for post-chemotherapy retroperitoneal lymph node dissection; the IGCCCG (International Germ Cell Cancer Consensus Group) risk classification; and pros and cons of 3 cycles of cisplatin, etoposide and bleomycin vs 4 cycles of etoposide and cisplatin EP for IGCCCG good risk disease.

AUA2017 Court is in Session: Sepsis after Mini PNCL by American Urological Association

Dr. Tanya D. Dorff presentation on Treatment Sequencing and Combinatorial Strategies in CRPC

Acknowledgements

The AUA Office of Education would like to thank the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support:

Astellas

AbbVie

Genomic Health

Sanofi Genzyme

Tolmar Pharmaceuticals, Inc.

CRPCProstate CancerAUA